Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if an investigational dendritic cell
vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor
called glioblastoma (GBM) when given with stronger doses of routine chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Immunomic Therapeutics, Inc. University of Florida
Collaborators:
National Cancer Institute (NCI) University of Florida